Versatile CRISPR‐Cas Tools for Gene Regulation in Zebrafish via an Enhanced Q Binary System
Advanced Science · 2026
DOI: 10.1002/advs.202511485 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Miaoyuan Shi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Medical Research Institute, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: Zebrafish, CRISPR-Cas Systems, Gene Expression Regulation, Gene Editing. Die Arbeit nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
CRISPR‐Cas systems revolutionize gene regulation across diverse organisms, including zebrafish. However, most zebrafish studies still rely on transient delivery of CRISPR components, with limited use of transgenic models, primarily restricted to Cas9‐mediated knockouts. This limitation arises from challenges in achieving sustained, tissue‐specific, and efficient expression of transgenic CRISPR effectors. To address these challenges, we introduce CRISPR‐Q, a transgenic system that combines the QFvpr/QUAS binary expression platform with CRISPR‐Cas technologies. CRISPR‐Q overcomes the drawbacks of transient mRNA or protein delivery and circumvents the toxicity and transgene silencing issues associated with other binary systems, such as Gal4/UAS. The system enables robust and spatiotemporal expression of CasRx or dCas9vpr, allowing precise transcript knockdown (CRISPR‐Q KD ) or gene activation (CRISPR‐Qa). Using CRISPR‐Q KD , we achieve effective knockdown of smn1 and simultaneous knockdown of tardbp and tardbpl , modeling spinal muscular atrophy and amyotrophic lateral sclerosis, respectively. CRISPR‐Qa activates endogenous lin28a and sox9b , demonstrating its functional versatility. We further validate CRISPR‐Q's tissue‐specific applicability in heart‐specific transgenic zebrafish. Together, CRISPR‐Q represents a robust and versatile platform for studying gene function and modeling human diseases in zebrafish, with broad potential for adaptation in other model organisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Medical Research Institute, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
- State Key Laboratory of Biocatalysis and Enzyme Engineeringhubei Hongshan Laboratory, School of Life Sciences, Hubei University, Wuhan, China.
- Department of Neurology, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
- Department of Nuclear Medicine, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
ORCID-Profile: Yanxun V Yu, Youngnam N Jin
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Shi, M., Ge, W., Li, C., Liu, B., Deng, X., Liu, C., Zheng, M., Zhang, P., Li, L., Guo, Y., Han, Y., Yang, Y., Yu, Y. V., & Jin, Y. N. (2026). Versatile CRISPR‐Cas Tools for Gene Regulation in Zebrafish via an Enhanced Q Binary System. Advanced Science. https://doi.org/10.1002/advs.202511485
Vancouver
Shi M, Ge W, Li C, Liu B, Deng X, Liu C, et al. Versatile CRISPR‐Cas Tools for Gene Regulation in Zebrafish via an Enhanced Q Binary System. Advanced Science. 2026. doi:10.1002/advs.202511485
BibTeX
@article{Shi2026,
author = {Shi, Miaoyuan and Ge, Weiqi and Li, Changheng and Liu, Bin and Deng, Xiaoyi and Liu, Chengjie and Zheng, Meijun and Zhang, Pu and Li, Lei and Guo, Ying and Han, Yunqi and Yang, Yu and Yu, Yanxun V and Jin, Youngnam N},
title = {Versatile CRISPR‐Cas Tools for Gene Regulation in Zebrafish via an Enhanced Q Binary System},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202511485}
}
EUVIMED